Microbial diversity in the cystic fibrosis airways: where is thy sting?
Decade-long bacterial community dynamics in cystic fibrosis airways
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007 – 2009.
First Bacterial Infection as an Alternative Clinical End Point for Regulatory Approval of Agents Targeting the Primary Cystic Fibrosis Defect
How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients
Trends in the use of routine therapies in cystic fibrosis: 1995-2005
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease
Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012.
Anti-PCRV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection.
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.
Detection and analysis of diverse herpesviral species by consensus primer PCR.
Characterizing aggressiveness and predicting future progression of CF lung disease
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis